Login to Your Account



Dogged by price control threats, biopharma fights for innovation

By Karen Pihl-Carey
Analyst

Friday, April 7, 2017

About a year after legislators lambasted Turing Pharmaceuticals’ former CEO, Martin Shkreli, for hiking by 5,000 percent the price of life-saving toxoplasmosis drug Daraprim, a firestorm has pummeled the biopharmaceutical industry.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription